UPDATED Jun 15, 2023
Defensive mid-caps and large-caps in descending order of expected ROE in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
PFEPfizer | US$39.75 | 1.7% | -16.3% | US$222.2b | US$46.68 | PE7.7x | E-13.9% | 4.1% | ||
300363Porton Pharma Solutions | CNÂ¥31.38 | 5.0% | -58.5% | CNÂ¥17.1b | CNÂ¥41.00 | PE8.9x | E-1.8% | 3.5% | ||
SANSanofi | €95.66 | 0.3% | 1.6% | €117.7b | €110.48 | PE14.3x | E10.1% | 3.7% | ||
4528Ono Pharmaceutical | JPÂ¥2,760.00 | 3.4% | -13.2% | JPÂ¥1.3t | JPÂ¥2,965.00 | PE12x | E-0.5% | 2.9% | ||
KRKGKrka d. d | €114.00 | 0.4% | 22.3% | €3.5b | €115.30 | PE9.8x | E2.6% | 5.8% | ||
4507Shionogi | JPÂ¥6,214.00 | 1.9% | -4.8% | JPÂ¥1.8t | JPÂ¥7,210.71 | PE9.9x | E-2.2% | 2.4% | ||
1177Sino Biopharmaceutical | HK$3.86 | 0% | -10.9% | HK$71.3b | HK$6.95 | PE25.5x | E14.6% | 3.0% | ||
538Yunnan Baiyao GroupLtd | CNÂ¥53.36 | 1.5% | -8.5% | CNÂ¥95.2b | CNÂ¥71.92 | PE26.4x | E15.5% | 2.8% | ||
VTRSViatris | US$9.94 | 4.4% | -3.3% | US$11.7b | US$12.51 | PE6.3x | E-4.1% | 4.8% | ||
600535Tasly Pharmaceutical Group | CNÂ¥14.60 | -3.2% | 37.7% | CNÂ¥21.8b | CNÂ¥12.10 | PE38.5x | E26.5% | 2.3% | ||
4536Santen Pharmaceutical | JPÂ¥1,227.00 | -1.8% | 23.2% | JPÂ¥458.0b | JPÂ¥1,325.56 | PS1.6x | E33.5% | 2.6% | ||
PRGOPerrigo | US$34.44 | 2.3% | -7.7% | US$4.6b | US$47.00 | PS1x | E102.7% | 3.2% | ||
4530Hisamitsu Pharmaceutical | JPÂ¥3,656.00 | 0.9% | 9.1% | JPÂ¥284.2b | JPÂ¥3,850.00 | PE24.2x | E17.3% | 2.3% | ||
4502Takeda Pharmaceutical | JPÂ¥4,572.00 | 0.8% | 28.7% | JPÂ¥7.1t | JPÂ¥4,690.56 | PE22.4x | E7.8% | 4.1% |